Jun Yong Park
연세대학교 의과대학 · 의학
Jun Yong Park 교수의 연구실은 만성 간염 B 환자의 정밀한 진단 및 치료 전략 수립을 목표로 하며, 바이러스 부하, 항체 및 간 섬유화 지표의 동적 변화를 분석합니다. 특히 qHBsAg, qHBeAg, elastography 기반 간섬유화 측정(LSM) 및 생체지표 조합을 활용한 예후 예측 모델 개발에 초점을 맞추고 있습니다. 고형암 치료 분야에서도 간동맥화학요법(HAIC)의 유효성과 안전성을 입증하며 종양 치료 전략의 혁신을 이끌고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Both qHBsAg and qHBeAg decreased significantly with ETV therapy. The baseline qHBsAg levels and the on-treatment decline of qHBeAg in HBeAg(+) patients were proven to be highly useful in predicting VR and SR, respectively. The determination of qHBsAg and qHBeAg can help us to select the appropriate strategy for the management of patients with CHB. However, the dynamic interplay between qHBsAg, qHBeAg, and HBV DNA during antiviral therapy remains to be elucidated.
HAIC with high-dose 5-FU and cisplatin given for 3 days achieved effective and safe results in patients with advanced HCC. Therefore, repetitive short-course HAIC with high-dose 5-FU and cisplatin may be useful as an alternative therapeutic option for patients with advanced HCC.
Different cutoff LSM values according to ALT level and combination with age-spleen-platelet ratio index can enhance the performance of LSM in CHB, regardless of ALT level.
LSM can be a useful predictor of LRE development in CHB patients showing histologically advanced liver fibrosis.
Current treatment guidelines suggest that antiviral therapy be considered for chronic hepatitis B (CHB) patients with high viral load if a biopsy shows significant liver disease despite alanine aminotransferase (ALT) levels two times or less than the upper limit of normal (ULN). We evaluated the histological findings in CHB patients with high viral load and persistently normal or slightly elevated serum ALT levels. Between January 2003 and June 2006, 105 consecutive treatment-naive patients with
